The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics

JAMA Intern Med. 2018 Jan 1;178(1):5-6. doi: 10.1001/jamainternmed.2017.6145.

Authors

Ameet Sarpatwari¹, Abbe R Gluck², Gregory D Curfman^{2

3

4}

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Solomon Center for Health Law and Policy, Yale Law School, New Haven, Connecticut.
³ Harvard Health Publishing, Harvard Medical School, Boston, Massachusetts.
⁴ Health Care Policy and Law Editor.

PMID: 29131908
DOI: 10.1001/jamainternmed.2017.6145

No abstract available

Publication types

Review

MeSH terms

Biosimilar Pharmaceuticals*
Drug Approval / legislation & jurisprudence*
Humans
Judicial Role*
Supreme Court Decisions*
United States

Substances

Biosimilar Pharmaceuticals